Samir Haffar1, Ravinder J Kaur2, Zhen Wang3, Larry J Prokop4, Mohammad H Murad3, Fateh Bazerbachi2. 1. Digestive center for diagnosis and treatment, Damascus, Syrian Arab Republic. 2. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 3. Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 4. Library Public Services, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND & AIMS: Acute liver failure caused by hepatitis E virus genotype 3 and 4 has been rarely described. Because of the presence of a short golden therapeutic window in patients with viral acute liver failure from other causes, it is possible that early recognition and treatment might reduce the morbidity and mortality. We performed a systematic review and pooled analysis of acute liver failure caused by hepatitis E virus genotype 3 and 4. METHODS: Two reviewers appraised studies after searching multiple databases on June 12th, 2017. Appropriate tests were used to compare hepatitis E virus genotype 3 vs 4, suspected vs confirmed genotypes, hepatitis E virus-RNA positive vs negative, and to discern important mortality risk factors. RESULTS: We identified 65 patients, with median age 58 years (range: 3-79), and a male to female ratio of 1.2:1. The median bilirubin, ALT, AST and alkaline phosphatase (expressed by multiplication of the upper limit of normal) levels were 14.8, 45.3, 34.8 and 1.63 respectively. Antihepatitis E virus IgG, antihepatitis E virus IgM and hepatitis E virus-RNA were positive in 84%, 91% and 86% of patients respectively. The median interval from symptoms onset to acute liver failure was 23 days, and 16 patients underwent liver transplantation. Final outcome was reported in 58 patients and mortality was 46%. Age was a predictor of poor prognosis in multivariate analysis. No important differences were found between patients infected with genotype 3 vs 4, patients with confirmed vs suspected genotypes, or patients with positive vs negative RNA. CONCLUSION: Acute liver failure caused by hepatitis E virus genotype 3 and 4 is rare, similar between genotypes, occurs commonly in middle-aged/elderly patients and has a very high mortality. Age is predictive of poor prognosis in multivariate analysis.
BACKGROUND & AIMS:Acute liver failure caused by hepatitis E virus genotype 3 and 4 has been rarely described. Because of the presence of a short golden therapeutic window in patients with viral acute liver failure from other causes, it is possible that early recognition and treatment might reduce the morbidity and mortality. We performed a systematic review and pooled analysis of acute liver failure caused by hepatitis E virus genotype 3 and 4. METHODS: Two reviewers appraised studies after searching multiple databases on June 12th, 2017. Appropriate tests were used to compare hepatitis E virus genotype 3 vs 4, suspected vs confirmed genotypes, hepatitis E virus-RNA positive vs negative, and to discern important mortality risk factors. RESULTS: We identified 65 patients, with median age 58 years (range: 3-79), and a male to female ratio of 1.2:1. The median bilirubin, ALT, AST and alkaline phosphatase (expressed by multiplication of the upper limit of normal) levels were 14.8, 45.3, 34.8 and 1.63 respectively. Antihepatitis E virus IgG, antihepatitis E virus IgM and hepatitis E virus-RNA were positive in 84%, 91% and 86% of patients respectively. The median interval from symptoms onset to acute liver failure was 23 days, and 16 patients underwent liver transplantation. Final outcome was reported in 58 patients and mortality was 46%. Age was a predictor of poor prognosis in multivariate analysis. No important differences were found between patients infected with genotype 3 vs 4, patients with confirmed vs suspected genotypes, or patients with positive vs negative RNA. CONCLUSION:Acute liver failure caused by hepatitis E virus genotype 3 and 4 is rare, similar between genotypes, occurs commonly in middle-aged/elderly patients and has a very high mortality. Age is predictive of poor prognosis in multivariate analysis.
Authors: Eduardo M Vilela; Catarina Ruivo; Claudio E Guerreiro; Marisa P Silva; Ricardo Ladeiras-Lopes; Daniel Caeiro; Gustavo P Morais; João Primo; Pedro Braga; Nuno Ferreira; José Pedro L Nunes; Vasco Gama Ribeiro Journal: Ther Adv Cardiovasc Dis Date: 2018-08-15
Authors: Siddharth Sridhar; Vincent C C Cheng; Shuk-Ching Wong; Cyril C Y Yip; Shusheng Wu; Anthony W I Lo; Kit-Hang Leung; Winger W N Mak; Jianpiao Cai; Xin Li; Jasper F W Chan; Susanna K P Lau; Patrick C Y Woo; Wai-Ming Lai; Tze-Hoi Kwan; Timmy W K Au; Chung-Mau Lo; Sally C Y Wong; Kwok-Yung Yuen Journal: Emerg Infect Dis Date: 2019-03 Impact factor: 6.883
Authors: Fateh Bazerbachi; Akira Dobashi; Swarup Kumar; Sanjay Misra; Navtej S Buttar; Louis M Wong Kee Song Journal: Gastroenterol Rep (Oxf) Date: 2020-12-03